The company intends to use the capital to fuel its ongoing pipeline development, with an additional provision granting underwriters a 30-day window to purchase up to $45 million in supplementary shares. While the stock has enjoyed a 22% gain year-to-date, this sudden injection of new equity into the market triggered an immediate cooling effect among shareholders.

A syndicate of financial institutions is managing the sale, with Morgan Stanley, Jefferies, and Evercore ISI serving as joint book-running managers alongside LifeSci Capital and Raymond James. Jones is acting as the lead manager for the transaction, which represents a significant capitalization effort for the firm.